Intermittent Marijuana Use Is Associated with Improved Retention in Naltrexone Treatment for Opiate-Dependence

REFERENCES

• Blanco C, Alderson D, Ogburn E, et al. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991–1992 and 2001–2002. Drug Alcohol Depend 2007; 90: 252–260
   PubMed Web of Science ®Google Scholar
• Mattick R P, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid maintenance. Cochrane Database Syst Rev 2008; 16, CD002207
   Google Scholar
• Johansson B A, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 2006; 101: 491–503
   PubMed Web of Science ®Google Scholar
• Davoli M, Perucci C A, Forastiere F, Doyle P, Rapiti E, Zaccarelli M. Risk factors for overdose mortality: a case-controlled study within a cohort of intravenous drug users. Int. J Epidemiol 1993; 22: 273–277
   PubMed Web of Science ®Google Scholar
• Zaric G S, Barnett P G, Brandeau M L. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000; 90: 1100–1111
   PubMed Web of Science ®Google Scholar
• Mertens J R, Weisner C M. Predictors of substance abuse treatment retention among women and men in an HMO. Alcohol Clin Exp Res 2000; 24: 1525–1533
   PubMed Web of Science ®Google Scholar
• Saxon A J, Wells E A, Fleming C, Jackson T R, Calsyn D A. Pre-treatment characteristics, program philosophy, and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction 1996; 91: 1197–1209
   PubMed Web of Science ®Google Scholar
• Stark M J. Dropping out of substance abuse treatment: a clinically oriented review. Clin Psychol Rev 1992; 12: 93–116
   Web of Science ®Google Scholar
• Caplehorn J RM, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991; 154: 195–199
   PubMed Web of Science ®Google Scholar
• McLellan A T, Arndt I O, Metzger D S, Woody G E, O'Brien C P. The effects of psychosocial services in substance abuse treatment. JAMA 1993; 269: 1953–1959
   PubMed Web of Science ®Google Scholar
• Torrens M, Castillo C, Perez-Sola V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend 1996; 41: 55–59
   PubMed Web of Science ®Google Scholar
• Del Rio M, Mino A, Perneger T V. Predictors of patient retention in a newly established methadone maintenance treatment program. Addiction 1997; 92: 1353–1360
   PubMed Web of Science ®Google Scholar
• Rhoades H M, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998; 88: 34–39
   PubMed Web of Science ®Google Scholar
• Caplehorn J RM, Lumley T S, Irwig L. Staff attitudes and retention of patients in methadone maintenance programs. Drug Alcohol Depend 1998; 52: 57–61
   PubMed Web of Science ®Google Scholar
• Preston K L, Umbricht A, Epstein D H. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry 2000; 57: 395–404
   PubMed Web of Science ®Google Scholar
• Sullivan M A, Rothenberg J L, Vosburg S K, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage 1 trial. Am J Addict 2006; 15: 150–159
   PubMed Web of Science ®Google Scholar
• Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatment alone for treatment of opioid dependence (review). The Cochrane Library 2006; 3: 1–30
   Google Scholar
• Villafranca S W, McKellar J D, Trafton J A, Humphreys K. Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend 2006; 83: 218–224
   PubMed Web of Science ®Google Scholar
• Preston K L, Silverman K, Umbricht A, DeJesus A, Montoya I D, Schuster C R. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999; 54: 127–135
   PubMed Web of Science ®Google Scholar
• Carroll K M, Ball S A, Nich C, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001; 58: 755–761
   PubMed Web of Science ®Google Scholar
• Carroll K M, Sinha R, Nich C, Babuscio T, Rounsaville B J. Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. Exp Clin Psychopharmacol 2002; 10: 54–63
   PubMed Web of Science ®Google Scholar
• Fals-Steward W, O'Farrell T J. Behavioral family counseling and naltrexone for male opioid dependent patients. J Consult Clin Psychol 2003; 71: 432–442
   Google Scholar
• Church S H, Rothenberg J L, Sullivan M A, Bornstein G, Nunes E V. Concurrent substance use and outcome in combined behavioral and naltrexone therapy for opiate dependence. Am J Drug Alcohol Abuse 2001; 27: 441–452
   PubMed Web of Science ®Google Scholar
• Nunes E V, Rothenberg J L, Sullivan M A, Carpenter K M, Kleber H D. Behavioral Therapy to Augment Oral Naltrexone for Opioid Dependence: A Ceiling on Effectiveness?. Am J Drug Alcohol Depend 2006; 32: 503–517
   PubMed Web of Science ®Google Scholar
• Nirenberg T D, Celluci T, Liepman M R, Swift R, Sirota D. Cannabis versus other illicit drug use among methadone maintenance patients. Psychol Addict Behav 1996; 10: 222–227
   Web of Science ®Google Scholar
• DeMaria P A, Sterling R, Weinstein S P. The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment. Am J Addict 2000; 9: 145–153
   PubMed Web of Science ®Google Scholar
• Ellner M. Marijuana use by heroin abusers as a factor in program retention. J Consult Clin Psychol 1977; 45: 709–710
   PubMed Web of Science ®Google Scholar
• Budney A J, Bickel W K, Amass L. Marijuana Use and treatment outcome among opioid-dependent patients. Addiction 1998; 93: 493–503
   PubMed Web of Science ®Google Scholar
• Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Cannabis abuse is not a risk factor for treatment outcome in methadone maintenance treatment: a 1-year prospective study in an Israeli clinic. Aust NZ J Psychiatry 2004; 38: 42–46
   PubMed Web of Science ®Google Scholar
• Epstein D H, Preston K L. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction 2003; 98: 269–279
   PubMed Web of Science ®Google Scholar
• Rothenberg J, Sullivan M A, Church S H, et al. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Ab Res 2002; 23: 351–360
   PubMed Web of Science ®Google Scholar
• Carroll K M, Nuro K R, O'Malley S S. Compliance enhancement: a manual for the clinical management of drug-dependent patients. Yale University School of Medicine, Psychotherapy Development Center, Department of Psychiatry, New Haven, CT 1999
   Google Scholar
• Nunes E V, Goehl L, Seracini A, et al. Evaluation of depression and panic disorder in methadone patients using a modification of the structured clinical interview for DSM-III-R: test-retest reliability. Am J Addict 1996; 5: 241–248
   Web of Science ®Google Scholar
• Miller W R, Rollnick S. Motivational Interviewing. Guilford Press, LondonEngland 2002
   Google Scholar
• Carroll K M, Rounsaville B J, Nich C, Gordon L T, Wirtz P W, Gawin F. One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry 1994; 51: 989–997
   PubMed Web of Science ®Google Scholar
• Marlot G A, Gordon J R. Relapse prevention and maintenance strategies in the treatment of addictive behaviors. Guilford Press, New York, NY 1985
   Google Scholar
• Silverman K, Wong C J, Umbricht-Schneider A, Montoya I D, Schuster C R, Preston K L. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol 1998; 66: 811–824
   PubMed Web of Science ®Google Scholar
• Silverman K, Chutuape M A, Bigelow G E, Stitzer M L. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharm. (Berlin) 1999; 146: 128–138
   PubMed Web of Science ®Google Scholar
• Stitzer M L, Iguchi M Y, Felch L J. Contingent take-home incentive: effect on drug use of methadone maintenance patients. J Consult Clin Psychol 1992; 60: 927–934
   PubMed Web of Science ®Google Scholar
• Higgins S T, Delaney D D, Budney A J, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry 1991; 148: 1218–1224
   PubMed Web of Science ®Google Scholar
• Higgins S T, Budney A J, Bickel W K, Hughes J R, Foerg F, Badger G. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 1993; 150: 763–769
   PubMed Web of Science ®Google Scholar
• Higgins S T, Budney A J, Bickel W K, Foerg F E, Donham R, Badger G J. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994; 51: 568–576
   PubMed Web of Science ®Google Scholar
• Galanter M. Network therapy for addiction: a model for office practice. Am J Psychiatry 1993; 150: 28–36
   PubMed Web of Science ®Google Scholar
• Wang D, Raehal K M, Bilsky E J, Sadee W. Inverse agonists and neutral antagonists at mu opioid receptors (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 2001; 77: 1590–1600
   PubMed Web of Science ®Google Scholar
• Raehal K M, Lowery J J, Bhamidipati C M, et al. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther 2005; 313: 1150–1162
   PubMed Web of Science ®Google Scholar
• Divin M F, Holden Ko M C, Traynor J R. Comparison of opioid receptor antagonist properties of naltrexone and 6beta-naltrexol in morphine-naïve and morphine-dependent mice. Eur J Pharmacol 2008; 583: 48–55
   Google Scholar
• Kleber H D, Topazian M, Gaspari J, Riordan C E, Kosten T. Clonidine and Naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987; 13: 1–17
   PubMed Web of Science ®Google Scholar
• Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2004, Oct 18;(4):CD002024
   Google Scholar
• Muntoni A L, Pillolla G, Melis M, Perra S, Gessa G L, Pistis M. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur J Neuroscience 2006; 23: 2385–2394
   Google Scholar
• Poddar M K, Dewey W L. Effects of cannabinoids on catcholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther 1980; 214: 63–67
   PubMed Web of Science ®Google Scholar
• Jentsch D J, Andrusiak B S, Tran A, Bowers M B, Roth R H. Delta-9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopahrmacology 1997; 16: 426–432
   PubMed Web of Science ®Google Scholar
• Schlicker E, Timm J, Zentner J, Gothert M. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiederbergs Arch. Pharmacol 1997; 356: 583–589
   Google Scholar
• Kathmann M, Bauer U, Schlicker E, Golthert M. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainite stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiederbergs Arch. Pharmacol 1999; 359: 466–470
   PubMedGoogle Scholar
• Trendelenburg A U, Cox S L, Schelb V, Klebroff W, Khairallah L, Starke K. Modulation of (3)H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and beta-adrenoreceptors in mouse tissues. Br J Pharmacol 2000; 130: 321–330
   Google Scholar
• Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001; 22: 565–572
   PubMed Web of Science ®Google Scholar
• Tzavara E T, Perry K W, Rodriguez D E, Bymaster F P, Nomikos G G. The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 2001; 426: R3–R4
   Google Scholar
• Tzavara E T, Davis R J, Perry K W, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003; 138: 544–553
   PubMed Web of Science ®Google Scholar
• Moranta D, Esteban S, Garcia-Sevilla J A. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiederbergs Arch Pharmacol 2004; 369: 516–524
   PubMed Web of Science ®Google Scholar
• Oropeza V C, Page M E, Van Bockstaele E J. Systemic administration of WIN55,212–2 increases norepinephrine release in the rat frontal cortex. Brain Res 2005; 1046: 45–54
   PubMed Web of Science ®Google Scholar
• Niederhoffer N, Szabo B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 1999; 126: 457–466
   Google Scholar
• Vizi E S, Katona I, Freund T F. Evidence for presynaptic cannabinoid CB(1) receptor-mediated inhibition of noradrenaline release in the guinea pig lung. Eur J Pharmacol 2001; 431: 237–244
   Google Scholar
• Pfizer T, Niederhoffer N, Szabo B. Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system. Naunyn Schmiedeberg Arch Pharmacol 2005; 371: 9–17
   Google Scholar
• Ponto L L, O'Leary D S, Koeppel J, et al. Effects of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [(15)O]water: effects in occasional and chronic users. J Clin Pharmacol 2004; 44: 751–766
   PubMed Web of Science ®Google Scholar
• Aviello G, Romano B, Izzo A A. Cannabinoid and gastrointestinal motility: animal and human studies. Eur Rev Med Pharmacol Sci 2008; 81–93, Suppl. 1
   Google Scholar
• Machado Rocha F C, Stefano S C, De Cassia Haiek R, Rosa Oliviera L M, Da Silviera D X. Therapeutic use of cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care. (Engl) 2008; 17: 431–443
   PubMed Web of Science ®Google Scholar
• Anton R F, O'Malley S S, Ciraulo D A, et al. Combined pharmacotherapy and behavioral interventions for alcohol dependence. JAMA 2006; 295: 2003–2017
   PubMed Web of Science ®Google Scholar
• Kranzler H R, Wesson D R, Billot L. Drug Abuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004; 28: 1051–1059
   PubMed Web of Science ®Google Scholar
• Vasquez C, Lewis D K. The CB1 cannabinoid receptor can sequester G-proteins making them unavailable to couple to other receptors. J Neurosci 1999; 19: 9271–9280
   PubMedGoogle Scholar
• Sullivan M A, Rothenberg J L, Vosburg S K, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage 1 trial. Am J Addict 2006; 15: 150–159
   PubMed Web of Science ®Google Scholar
• Carpenter K M, Jiang H, Sullivan M A, et al. Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav 2009; 23: 47–55
   PubMed Web of Science ®Google Scholar
• Mason D J, Lowe J, Welch S P. A diminution of delta-9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development. Eur J Pharmacology 1999; 381: 105–111
   PubMedGoogle Scholar
• Shedler J, Block J. Adolescent drug use and psychological health. Am Psychol 1990; 45: 612–630
   PubMed Web of Science ®Google Scholar
• Haney M, Bisaga A, Foltin R W. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berlin) 2003; 166: 77–85
   PubMed Web of Science ®Google Scholar
• Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 2007; 32: 1391–1403
   PubMedGoogle Scholar